Official Title
Observational Prospective Cohort Study - Registry of Patients With Hematologic Disease and COVID-19 in Russia (CHRONOS19)
Brief Summary

This is an observational prospective cohort study to evaluate the clinical course and outcomes of COVID-19 and the underlying disease in patients with hematologic disease (malignant or non-malignant).

Detailed Description

This is a web-based registry. After registration, physicians from hematology clinical centers
and hospitals in Russia will receive access to the web platform for clinical trial management
to fill in the online data collection form in a de-identified manner. This form includes
questions about general clinical history of hematologic disease, manifestation, treatment,
and the course of COVID-19, concomitant conditions, consequences on the hematologic disease,
short-term and long-term outcomes. It will take approximately 10 min to answer the questions.
Patients will be followed for 30 days after COVID-19 diagnosis and up to 6 months for
hematologic disease outcomes and overall survival assessment.

Completed
Coronavirus Infection and Hematologic Diseases

Other: Non-interventional study

Non-interventional study

Eligibility Criteria

Inclusion Criteria

- Age 18 or older

- Any previously or currently diagnosed hematologic disease

- Laboratory confirmed or suspected (based on clinical symptoms and/or CT) COVID-19

- Known outcome of COVID-19 in case of retrospective data input (protocol allows
retrospective data input for patients who were prospectively followed in local
centers)

Exclusion Criteria

• Loss of follow-up within 30 days after COVID-19 diagnosis

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Russian Federation
Locations

Regional Clinical Hospital No1
Ekaterinburg, Russian Federation

Republican Clinical Hospital of Tatarstan
Kazan, Russian Federation

City Hospital n.a. V.V. Veresaev
Moscow, Russian Federation

Clinical Hospital n.a. S.P. Botkin
Moscow, Russian Federation

N.V. Sklifosovsky Emergency Institute
Moscow, Russian Federation

National Research Center for Hematology
Moscow, Russian Federation

Regional Clinical Hospital N.A. Semashko
Nizhny Novgorod, Russian Federation

Regional Hospital
Novosibirsk, Russian Federation

Regional Clinical Hospital
Omsk, Russian Federation

RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University
Saint Petersburg, Russian Federation

Republican Clinical Hospital No4
Saransk, Russian Federation

Republic Clinical Hospital n.a. N.A. Semashko
Ulan-Ude, Russian Federation

Regional Clinical Hospital
Vladimir, Russian Federation

Regional Clinical Hospital No2
Vladivostok, Russian Federation

Regional Clinical Hospital
Yaroslavl, Russian Federation

Elena Parovichnikova, Study Chair
National Research Center for Hematology

National Research Center for Hematology, Russia
NCT Number
Keywords
Covid-19
Blood diseases
Leukemia
Lymphoma
MeSH Terms
COVID-19
Coronavirus Infections
Hematologic Diseases